A Rivoli e Pinerolo, nel Torinese, le prime tre operazioni
Risultati per: Scoperta una nuova molecola anti-cancro
Questo è quello che abbiamo trovato per te
La crioablazione nuova frontiera nella cura del tumore al seno
Trattamento rapido e tollerato con ridotto impatto estetico
La crioablazione nuova frontiera nella cura del tumore al seno
Trattamento rapido e tollerato con ridotto impatto estetico
Colesterolo alto: nuova terapia combinata
Nuova arma ultra precisa contro tumori, li colpisce in 6 secondi
All’Irccs Negrar per la radioterapia, tecnologia unica in Italia
Tumori, legame tra bevande zuccherate e cancro orale nelle donne
Studio, una bevanda al giorno aumenta il rischio di 5 volte
Tumori, legame tra bevande zuccherate e cancro orale nelle donne
Studio, una bevanda al giorno aumenta il rischio di 5 volte
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
TNF-like cytokine 1A (TL1A) and its functional receptor, death-domain receptor 3 (DR3), are members of the TNF and TNFR superfamilies, respectively, with recognised roles in regulating innate and adaptive immune responses; additional existence of a decoy receptor, DcR3, indicates a tightly regulated cytokine system. The significance of TL1A:DR3 signalling in the pathogenesis of inflammatory bowel disease (IBD) is supported by several converging lines of evidence. Herein, we aim to provide a comprehensive understanding of what is currently known regarding the TL1A/DR3 system in the context of IBD. TL1A and DR3 are expressed by cellular subsets with important roles for the initiation and maintenance of intestinal inflammation, serving as potent universal costimulators of effector immune responses, indicating their participation in the pathogenesis of IBD. Recent evidence also supports a homoeostatic role for TL1A:DR3 via regulation of Tregs and innate lymphoid cells. TL1A and DR3 are also expressed by stromal cells and may contribute to inflammation-induced or inflammation-independent intestinal fibrogenesis. Finally, discovery of genetic polymorphisms with functional consequences may allow for patient stratification, including differential responses to TL1A-targeted therapeutics. In conclusion, TL1A:DR3 signalling plays a central and multifaceted role in the immunological pathways that underlie intestinal inflammation, such as that observed in IBD. Such evidence provides the foundation for developing pharmaceutical approaches targeting this ligand-receptor pair in IBD.
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)
Objectives
To investigate the long-term safety and efficacy of otilimab, an antigranulocyte-macrophage colony-stimulating factor monoclonal antibody, for patients with rheumatoid arthritis (RA).
Methods
ContRAst X (NCT04333147) was a phase 3, multicentre, long-term extension trial. Patients with RA aged ≥18 years who completed a qualifying contRAst trial (contRAst 1–3) and who the investigator thought might benefit from long-term otilimab treatment were eligible to enter contRAst X. Patients who received otilimab (90 mg/150 mg) in their qualifying trial maintained the same dose; patients who received tofacitinib or sarilumab were rerandomised 1:1 to either otilimab dose. Patients could continue background conventional synthetic disease-modifying antirheumatic drugs. The primary objective was long-term safety (up to 4 years).
Results
Of the 2916 patients who entered contRAst X, 2915 received otilimab (exposure range: 7–896 days); the majority were withdrawn due to early trial termination. For otilimab 90 mg and 150 mg, the incidence of adverse events (AEs) was 62% (n=902/1456) and 64% (n=931/1459), the incidence of AEs of special interest was 8% (n=120/1456) and 7% (n=95/1459) and the incidence of serious AEs was 8% (n=123/1456) and 8% (n=114/1459), respectively. There were no instances of pulmonary alveolar proteinosis (PAP), active tuberculosis (TB), TB reactivation or serious hypersensitivity reactions. The proportions of clinical disease activity index low disease activity responders remained relatively stable throughout, with no apparent reduction following the switch from tofacitinib/sarilumab to otilimab.
Conclusion
No new safety signals or instances of PAP were associated with long-term (≤2.5 years) treatment with otilimab.
Trial registration number
ClinicalTrials.gov: NCT04333147.
Tumore alla prostata, una nuova cura blocca le metastasi
Nuova app dell'Aifa per un uso appropriato degli antibiotici
A disposizione dei medici ma consultabile anche dai cittadini
Lo yogurt potrebbe ridurre il cancro al colon
Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy
This cohort study examines the response and survival rates associated with ipilimumab-nivolumab therapy in patients with progressive melanoma brain metastases after anti–programmed cell death 1 (anti–PD-1) therapy.
Safety and Efficacy of Anti–IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis
This randomized clinical trial assessed the safety, pharmacokinetics, and efficacy of the humanized anti–IL-23 monoclonal antibody QX004N for patients with moderate to severe plaque psoriasis.
Dopo il broncospasmo si può rischiare nuova polmonite
La pneumologa Dagmar Rinnenburger: “L’aspirazione per evitare infezione da ingestione”